THNR
Amplify Weight Loss Drug & Treatment ETF
Amplify Weight Loss Drug & Treatment ETF seeks to provide investors with exposure to companies involved in the development and commercialization of weight loss drugs and treatments.
Global
EQUITY
Passive
MANAGEMENT STYLE
3.0 M
ASSETS UNDER MGMT
59 bp
EXPENSES
Fund Basics
| Fund sponsor | Amplify |
| Category | Global |
| Asset class | Equity |
| Website | link... |
| Inception date | May 20, 2024 |
| Assets (mns) | $3 |
| Expense ratio | 59 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | |
| Taxation | 1099 |
| Stock selection | |
| Weighting | |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 12.0 % |
| NOVO-NORDISK A/S-SPONS ADR | 8.7 % |
| REGENERON PHARMACEUTICALS | 7.4 % |
| AMGEN INC | 6.4 % |
| INNOVENT BIOLOGICS, INC. | 6.0 % |
| CHUGAI PHARMACEUTICAL CO LTD | 6.0 % |
| ABBVIE INC | 5.9 % |
| ASTRAZENECA PLC-SPONS ADR | 5.5 % |
| GILEAD SCIENCES INC | 5.3 % |
| MERCK & CO. INC. | 5.2 % |
Constituent Breakdown
| Number of holdings | 20 |
| Herfindahl-Hirschman Index | 629 |
| Wgt avg mkt cap (mns) | $189,672 |
| Large cap (>$10bn) | 87.4% |
| Mid cap ($2-10bn) | 8.0% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 92.1% |
| Emerging mkts. | 4.9% |
Country Exposure
 |
UNITED STATES | 54.8 % |
 |
DENMARK | 11.4 % |
 |
JAPAN | 10.7 % |
 |
HONG KONG | 6.8 % |
 |
CHINA | 6.0 % |
 |
BRITAIN | 5.5 % |
 |
SWITZERLAND | 5.1 % |
 |
SOUTH KOREA | 0.9 % |
Historical Performance
Standardized Performance (as of 08/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 1.7% | -18.7% | -- | -- | -- | -- | -- | -7.8% |
| Dividend Yield | 0.0% | 0.8% | -- | -- | -- | -- | -- | 0.7% |
| Total Returns | 1.7% | -17.9% | -- | -- | -- | -- | -- | -7.1% | Ann. Volatility | 22.7% | 20.5% | -- | -- | -- | -- | -- | 19.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.63 | 23% |
| MSCI EAFE | 0.36 | 9% |
| MSCI Emg Mkts | 0.19 | 1% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.8% |
| Avg. Bid/Ask (% of price) | 0.75% |
Technical Indicators
| Recent close | $23.11 |
| 30d moving avg. | $22.84 |
| Annualized volatility | 15.1% |
| Relative strength (RSI) | 53 |
| Short interest | 4.4% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. |
Expenses vs. |
ALTAR Score™ vs. |
|---|---|---|---|---|
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 59.0% | 0 bp | +4.3% |
| PPH | VanEck Pharmaceutical ETF | 37.8% | -23 bp | +8.8% |
| MEDX | Horizon Kinetics Medical ETF | 35.8% | +26 bp | +1.8% |
| PJP | Invesco Pharmaceuticals ETF | 32.0% | -2 bp | +8.3% |
| XLV | Health Care Select Sector SPDR Fund | 31.6% | -51 bp | +7.6% |
| IYH | iShares U.S. Healthcare ETF | 30.9% | -19 bp | +6.8% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 29.1% | +1 bp | +11.0% |
| VHT | Vanguard Health Care ETF | 28.3% | -50 bp | +6.1% |
| IXJ | iShares Global Healthcare ETF | 27.4% | -17 bp | +7.2% |
| FHLC | Fidelity MSCI Health Care Index ETF | 26.9% | -51 bp | +6.3% |
Risk and Returns: THNR vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2024 | 2025 | 2026 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 9/17/2025
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
SPECULATIVE
Deeply undervalued but risky. A rating of SPECULATIVE is assigned to ETFs with ALTAR Scores in the top quintile (the top 20%) of their category, indicating exceptional appreciation potential. However, often these are narrowly-focused funds or in industries with structural issues, which may also make them very risky. Nonetheless they may still be useful as part of a well-diversified portfolio.
ALTAR Score™
THNR
7.2%
Cat. Avg
4.2%
ALTAR Score™ Calculation
Category Overview
There are 367 funds in the Global Equity category, with an average ALTAR Score™
of 4.2% and a standard deviation of
3.2%. THNR's ALTAR Score™ is approximately
0.9 standard deviations
above
the category average. This places THNR in the 82nd percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
THNRSELL
U/W
HOLD
O/W
BUY
Expense Analysis
| Peer Group | Passive Global Equity ETFs |
| # of ETFs | 53 |
| Avg. Expense Ratio | 50.8 bp |
| Std. Deviation | 22.4 bp |
| (59 bp) Percentile rank | 68 |
Peer Group Expense Ratio Distribution
Total Cost of Ownership (TCO) Comparison
| Expense (bp) (A) |
Avg. Bid/Ask (bp) (B) |
TCO (bp) (A)+(B) |
|
|---|---|---|---|
| THNR | 59.0 | 0.0 | 59 |
| Peer Avg. | 56.7 | 41.9 | 98.6 |
For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .